Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MDRNA has announced positive in vivo efficacy data using a novel combination of a meroduplex siRNA and MDRNA's proprietary lipid-based delivery platform, the DiLA2 platform.
Subscribe to our email newsletter
The data indicated that a single in vivo administration of MDRNA meroduplexes targeting apolipoprotein B mRNA formulated in a DiLA2 delivery vehicle showed robust activity in a mouse model.
The meroduplex siRNA decreased both ApoB mRNA and serum cholesterol levels. In addition, the formulated, chemically modified siRNA resulted in minimal body weight loss in mice while showing reduced levels of cytokine stimulation.
Michael Houston, vice president of chemistry and formulations at MDRNA, said: “The results of this preclinical work suggest that a unique combination of both a novel siRNA construct within a lipid-based delivery formulation has the potential to elicit a potent RNAi response and reduce off-target activity.”